Advertisement

Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial

      Abstract

      Background

      We evaluated the antihyperglycemic efficacy and safety of adding the dipeptidyl dipeptidase-4 inhibitor alogliptin to metformin and sulphonylurea in the treatment of type 2 diabetes in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care Trial.

      Methods

      Patients with type 2 diabetes and recent acute coronary syndrome were randomized to alogliptin or placebo and standard of care. Participants were followed for up to 40 (median 18) months. In a subgroup taking metformin and sulphonylurea at baseline, we evaluated change from baseline in glycated hemoglobin (HbA1c), adverse events, cardiovascular outcomes, laboratory data, and other safety parameters.

      Results

      There were 1398 patients receiving baseline dual therapy (metformin and sulphonylurea only) randomized to alogliptin (N = 693) or placebo (N = 705); 550 patients receiving alogliptin and 505 patients receiving placebo completed the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care without addition of other antihyperglycemic therapies (P = .008). Changes from baseline to last visit in HbA1c were −0.4% on alogliptin and +0.1% on placebo (P < .001) in all those with baseline dual therapy and −0.4% for alogliptin and +0.2% for placebo (P < .001) in those without additional therapies. Reported rates of hypoglycemia were 8.8% for alogliptin and 6.7% for placebo (P = .16). Cardiovascular death and all-cause mortality rates were lower in those receiving alogliptin compared with those receiving placebo (hazard ratio, 0.49; 95% confidence interval, 0.28-0.84 and hazard ratio, 0.61; 95% confidence interval, 0.38-0.96, respectively).

      Conclusions

      Addition of the dipeptidyl peptidase-4 inhibitor alogliptin to dual therapy with metformin plus sulfonylurea significantly reduced HbA1c and was well tolerated. Lower mortality rates were seen in patients treated with alogliptin in this subgroup.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. ADA Standards of Medical Care in Diabetes.
        (Available at)
        • NICE Guideline
        Type 2 diabetes in adults: management (NG28).
        (Available at)
        https://www.nice.org.uk/guidance/ng28
        Date accessed: May 6, 2016
        • Kay S.
        • Strickson A.
        • Puelles J.
        • Selby R.
        • Benson E.
        • Tolley K.
        Comparative effectiveness of adding alogliptin to metformin plus sulfonylurea with other DPP-4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis.
        Diabetes Ther. 2017; 8: 251-273
        • Khunti K.
        • Wolden M.L.
        • Thorsted B.L.
        • Andersen M.
        • Davies M.J.
        Clinical inertia in people with type 2 diabetes.
        Diabetes Care. 2013; 36: 3411-3417
        • Scirica B.M.
        • Bhatt D.L.
        • Braunwald E.
        • et al.
        Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
        N Engl J Med. 2013; 369: 1317-1326
        • White W.B.
        • Cannon C.P.
        • Heller S.R.
        • et al.
        Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
        N Engl J Med. 2013; 369: 1327-1335
        • White W.B.
        • Bakris G.L.
        • Bergenstal R.M.
        • et al.
        Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
        Am Heart J. 2011; 162: 620-626
        • Holman R.R.
        • Paul S.K.
        • Bethel M.A.
        • Matthews D.R.
        • Neil H.A.
        10-year follow-up of intensive glucose control in type 2 diabetes.
        N Engl J Med. 2008; 359: 1577-1589
        • Holman R.R.
        • Paul S.K.
        • Bethel M.A.
        • Neil H.A.
        • Matthews D.R.
        Long-term follow-up after tight control of blood pressure in type 2 diabetes.
        N Engl J Med. 2008; 359: 1565-1576
        • Cahn A.
        • Raz I.
        • Mosenzon O.
        • et al.
        Predisposing factors for any and major hypoglycaemia with saxagliptin versus placebo and overall: analysis from the SAVOR-TIMI 53 Trial.
        Diabetes Care. 2016; 39: 1329-1337
        • Engel S.S.
        • Suryawanshi S.
        • Stevens S.R.
        • Josse R.G.
        • Cornel J.H.
        • Jakuboniene N.
        Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
        Diabetes Obes Metab. 2017; 19: 1587-1593
        • Salvo F.
        • Moore N.
        • Arnaud M.
        • et al.
        Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
        BMJ. 2016; 353: i2231